25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Nuvectis Pharma Inc
Buy, Hold or Sell?

Let's analyze Nuvectis together

I guess you are interested in Nuvectis Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Nuvectis Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Nuvectis Pharma Inc

I send you an email if I find something interesting about Nuvectis Pharma Inc.

1. Quick Overview

1.1. Quick analysis of Nuvectis (30 sec.)










1.2. What can you expect buying and holding a share of Nuvectis? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.57
Expected worth in 1 year
$0.27
How sure are you?
28.6%

+ What do you gain per year?

Total Gains per Share
$-0.29
Return On Investment
-6.2%

For what price can you sell your share?

Current Price per Share
$4.76
Expected price per share
$4.6106 - $5.9
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Nuvectis (5 min.)




Live pricePrice per Share (EOD)
$4.76
Intrinsic Value Per Share
$-0.37 - $-0.13
Total Value Per Share
$0.20 - $0.44

2.2. Growth of Nuvectis (5 min.)




Is Nuvectis growing?

Current yearPrevious yearGrowGrow %
How rich?$10.9m$15.8m-$3.4m-27.7%

How much money is Nuvectis making?

Current yearPrevious yearGrowGrow %
Making money-$4.8m-$5.5m$686k14.2%
Net Profit Margin40.4%-1,120.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Nuvectis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#614 / 949

Most Revenue
#941 / 949

Most Profit
#424 / 949
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Nuvectis?

Welcome investor! Nuvectis's management wants to use your money to grow the business. In return you get a share of Nuvectis.

First you should know what it really means to hold a share of Nuvectis. And how you can make/lose money.

Speculation

The Price per Share of Nuvectis is $4.76. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nuvectis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nuvectis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.57. Based on the TTM, the Book Value Change Per Share is $-0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nuvectis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.21-4.5%-0.25-5.3%-0.29-6.1%-0.25-5.2%-0.25-5.2%
Usd Book Value Change Per Share-0.08-1.7%-0.07-1.5%-0.05-1.0%0.040.9%0.040.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.08-1.7%-0.07-1.5%-0.05-1.0%0.040.9%0.040.9%
Usd Price Per Share6.29-7.29-12.37-7.45-7.45-
Price to Earnings Ratio-7.32--7.45--11.29--7.72--7.72-
Price-to-Total Gains Ratio-79.07--27.46--45.95--31.21--31.21-
Price to Book Ratio11.06-11.33-15.23-10.12-10.12-
Price-to-Total Gains Ratio-79.07--27.46--45.95--31.21--31.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.76
Number of shares210
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.070.04
Usd Total Gains Per Share-0.070.04
Gains per Quarter (210 shares)-15.478.53
Gains per Year (210 shares)-61.9034.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-62-7203424
20-124-13406858
30-186-196010292
40-248-2580137126
50-309-3200171160
60-371-3820205194
70-433-4440239228
80-495-5060273262
90-557-5680307296
100-619-6300341330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.014.00.00.0%0.014.00.00.0%0.014.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%4.010.00.028.6%4.010.00.028.6%4.010.00.028.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.014.00.0%0.00.014.00.0%0.00.014.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%4.010.00.028.6%4.010.00.028.6%4.010.00.028.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Nuvectis Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.080-0.074-7%-0.048-40%0.041-296%0.041-296%
Book Value Per Share--0.5690.644-12%0.822-31%0.500+14%0.500+14%
Current Ratio--2.7403.030-10%4.206-35%5.725-52%5.725-52%
Debt To Asset Ratio--0.3650.333+10%0.245+49%0.674-46%0.674-46%
Debt To Equity Ratio--0.5750.503+14%0.329+75%0.286+101%0.286+101%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--132382090.000153128340.000-14%254406217.500-48%197300357.273-33%197300357.273-33%
Eps---0.215-0.251+17%-0.289+34%-0.248+15%-0.248+15%
Ev To Ebitda Ratio---7.969-7.830-2%-11.752+47%-10.374+30%-10.374+30%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.124-0.176+42%-0.202+62%-0.180+45%-0.180+45%
Free Cash Flow To Equity Per Share---0.049-0.063+29%-0.020-58%0.115-142%0.115-142%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.134--------
Intrinsic Value_10Y_min---0.365--------
Intrinsic Value_1Y_max---0.598--------
Intrinsic Value_1Y_min---0.588--------
Intrinsic Value_3Y_max---1.352--------
Intrinsic Value_3Y_min---1.300--------
Intrinsic Value_5Y_max---1.568--------
Intrinsic Value_5Y_min---1.494--------
Market Cap91967960.000-32%121529090.000140850090.000-14%238952467.500-49%143982852.143-16%143982852.143-16%
Net Profit Margin---0.404-100%-11.2030%-43.4610%-43.4610%
Operating Margin---0.358-100%-11.6210%-43.7360%-43.7360%
Operating Ratio----1.0870%11.372-100%43.385-100%43.385-100%
Pb Ratio8.368-32%11.05711.331-2%15.232-27%10.116+9%10.116+9%
Pe Ratio-5.536+24%-7.316-7.450+2%-11.288+54%-7.721+6%-7.721+6%
Price Per Share4.760-32%6.2907.290-14%12.368-49%7.452-16%7.452-16%
Price To Free Cash Flow Ratio-9.564+24%-12.638-10.579-16%-15.411+22%-10.329-18%-10.329-18%
Price To Total Gains Ratio-59.836+24%-79.069-27.464-65%-45.947-42%-31.214-61%-31.214-61%
Quick Ratio--2.7183.004-10%4.114-34%5.630-52%5.630-52%
Return On Assets---0.240-0.260+8%-0.265+10%-0.328+37%-0.328+37%
Return On Equity---0.378-0.393+4%-0.355-6%-0.270-28%-0.270-28%
Total Gains Per Share---0.080-0.074-7%-0.048-40%0.041-296%0.041-296%
Usd Book Value--10991000.00012435500.000-12%15877750.000-31%9667571.429+14%9667571.429+14%
Usd Book Value Change Per Share---0.080-0.074-7%-0.048-40%0.041-296%0.041-296%
Usd Book Value Per Share--0.5690.644-12%0.822-31%0.500+14%0.500+14%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--132382090.000153128340.000-14%254406217.500-48%197300357.273-33%197300357.273-33%
Usd Eps---0.215-0.251+17%-0.289+34%-0.248+15%-0.248+15%
Usd Free Cash Flow---2404000.000-3408000.000+42%-3905000.000+62%-3485642.857+45%-3485642.857+45%
Usd Free Cash Flow Per Share---0.124-0.176+42%-0.202+62%-0.180+45%-0.180+45%
Usd Free Cash Flow To Equity Per Share---0.049-0.063+29%-0.020-58%0.115-142%0.115-142%
Usd Market Cap91967960.000-32%121529090.000140850090.000-14%238952467.500-49%143982852.143-16%143982852.143-16%
Usd Price Per Share4.760-32%6.2907.290-14%12.368-49%7.452-16%7.452-16%
Usd Profit---4153000.000-4843500.000+17%-5529500.000+33%-4758142.857+15%-4758142.857+15%
Usd Revenue----1025250.0000%1062500.000-100%10928.571-100%10928.571-100%
Usd Total Gains Per Share---0.080-0.074-7%-0.048-40%0.041-296%0.041-296%
 EOD+3 -5MRQTTM+13 -21YOY+11 -235Y+15 -1910Y+15 -19

3.3 Fundamental Score

Let's check the fundamental score of Nuvectis Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.536
Price to Book Ratio (EOD)Between0-18.368
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.718
Current Ratio (MRQ)Greater than12.740
Debt to Asset Ratio (MRQ)Less than10.365
Debt to Equity Ratio (MRQ)Less than10.575
Return on Equity (MRQ)Greater than0.15-0.378
Return on Assets (MRQ)Greater than0.05-0.240
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Nuvectis Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4.710
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Nuvectis Pharma Inc

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Fundamental data was last updated by Penke on 2024-12-04 07:51:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Nuvectis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nuvectis to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nuvectis Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM40.4%-40.4%
TTM40.4%YOY-1,120.3%+1,160.7%
TTM40.4%5Y-4,346.1%+4,386.4%
5Y-4,346.1%10Y-4,346.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--108.0%+108.0%
TTM40.4%-218.6%+259.0%
YOY-1,120.3%-210.1%-910.2%
5Y-4,346.1%-339.1%-4,007.0%
10Y-4,346.1%-464.5%-3,881.6%
4.3.1.2. Return on Assets

Shows how efficient Nuvectis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nuvectis to the Biotechnology industry mean.
  • -24.0% Return on Assets means that Nuvectis generated $-0.24 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nuvectis Pharma Inc:

  • The MRQ is -24.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -26.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.0%TTM-26.0%+2.0%
TTM-26.0%YOY-26.5%+0.5%
TTM-26.0%5Y-32.8%+6.9%
5Y-32.8%10Y-32.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.0%-11.3%-12.7%
TTM-26.0%-11.8%-14.2%
YOY-26.5%-11.3%-15.2%
5Y-32.8%-12.6%-20.2%
10Y-32.8%-14.2%-18.6%
4.3.1.3. Return on Equity

Shows how efficient Nuvectis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nuvectis to the Biotechnology industry mean.
  • -37.8% Return on Equity means Nuvectis generated $-0.38 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nuvectis Pharma Inc:

  • The MRQ is -37.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -39.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-37.8%TTM-39.3%+1.5%
TTM-39.3%YOY-35.5%-3.8%
TTM-39.3%5Y-27.0%-12.3%
5Y-27.0%10Y-27.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-37.8%-14.2%-23.6%
TTM-39.3%-15.9%-23.4%
YOY-35.5%-14.4%-21.1%
5Y-27.0%-18.5%-8.5%
10Y-27.0%-19.5%-7.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Nuvectis Pharma Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Nuvectis is operating .

  • Measures how much profit Nuvectis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nuvectis to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nuvectis Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM35.8%-35.8%
TTM35.8%YOY-1,162.1%+1,197.8%
TTM35.8%5Y-4,373.6%+4,409.3%
5Y-4,373.6%10Y-4,373.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.6%+204.6%
TTM35.8%-313.2%+349.0%
YOY-1,162.1%-219.0%-943.1%
5Y-4,373.6%-388.9%-3,984.7%
10Y-4,373.6%-495.6%-3,878.0%
4.3.2.2. Operating Ratio

Measures how efficient Nuvectis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Nuvectis Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1.087+1.087
TTM-1.087YOY11.372-12.460
TTM-1.0875Y43.385-44.472
5Y43.38510Y43.3850.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.340-2.340
TTM-1.0873.187-4.274
YOY11.3723.282+8.090
5Y43.3854.814+38.571
10Y43.3856.494+36.891
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Nuvectis Pharma Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Nuvectis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.74 means the company has $2.74 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Nuvectis Pharma Inc:

  • The MRQ is 2.740. The company is able to pay all its short-term debts. +1
  • The TTM is 3.030. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.740TTM3.030-0.290
TTM3.030YOY4.206-1.175
TTM3.0305Y5.725-2.695
5Y5.72510Y5.7250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7403.645-0.905
TTM3.0303.883-0.853
YOY4.2064.666-0.460
5Y5.7255.964-0.239
10Y5.7256.265-0.540
4.4.3.2. Quick Ratio

Measures if Nuvectis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nuvectis to the Biotechnology industry mean.
  • A Quick Ratio of 2.72 means the company can pay off $2.72 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nuvectis Pharma Inc:

  • The MRQ is 2.718. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.004. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.718TTM3.004-0.286
TTM3.004YOY4.114-1.110
TTM3.0045Y5.630-2.626
5Y5.63010Y5.6300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7183.014-0.296
TTM3.0043.418-0.414
YOY4.1144.456-0.342
5Y5.6305.970-0.340
10Y5.6306.424-0.794
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Nuvectis Pharma Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Nuvectis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nuvectis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.36 means that Nuvectis assets are financed with 36.5% credit (debt) and the remaining percentage (100% - 36.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nuvectis Pharma Inc:

  • The MRQ is 0.365. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.333. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.365TTM0.333+0.032
TTM0.333YOY0.245+0.088
TTM0.3335Y0.674-0.341
5Y0.67410Y0.6740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3650.350+0.015
TTM0.3330.341-0.008
YOY0.2450.310-0.065
5Y0.6740.365+0.309
10Y0.6740.382+0.292
4.5.4.2. Debt to Equity Ratio

Measures if Nuvectis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nuvectis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 57.5% means that company has $0.57 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nuvectis Pharma Inc:

  • The MRQ is 0.575. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.503. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.575TTM0.503+0.071
TTM0.503YOY0.329+0.174
TTM0.5035Y0.286+0.218
5Y0.28610Y0.2860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5750.394+0.181
TTM0.5030.432+0.071
YOY0.3290.380-0.051
5Y0.2860.451-0.165
10Y0.2860.490-0.204
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nuvectis generates.

  • Above 15 is considered overpriced but always compare Nuvectis to the Biotechnology industry mean.
  • A PE ratio of -7.32 means the investor is paying $-7.32 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nuvectis Pharma Inc:

  • The EOD is -5.536. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.316. Based on the earnings, the company is expensive. -2
  • The TTM is -7.450. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.536MRQ-7.316+1.780
MRQ-7.316TTM-7.450+0.134
TTM-7.450YOY-11.288+3.838
TTM-7.4505Y-7.721+0.271
5Y-7.72110Y-7.7210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.536-2.315-3.221
MRQ-7.316-2.491-4.825
TTM-7.450-3.156-4.294
YOY-11.288-3.274-8.014
5Y-7.721-6.037-1.684
10Y-7.721-6.785-0.936
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nuvectis Pharma Inc:

  • The EOD is -9.564. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.638. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.579. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.564MRQ-12.638+3.074
MRQ-12.638TTM-10.579-2.060
TTM-10.579YOY-15.411+4.833
TTM-10.5795Y-10.329-0.249
5Y-10.32910Y-10.3290.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.564-2.985-6.579
MRQ-12.638-3.361-9.277
TTM-10.579-3.734-6.845
YOY-15.411-4.557-10.854
5Y-10.329-8.327-2.002
10Y-10.329-9.311-1.018
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Nuvectis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 11.06 means the investor is paying $11.06 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Nuvectis Pharma Inc:

  • The EOD is 8.368. Based on the equity, the company is overpriced. -1
  • The MRQ is 11.057. Based on the equity, the company is expensive. -2
  • The TTM is 11.331. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD8.368MRQ11.057-2.690
MRQ11.057TTM11.331-0.274
TTM11.331YOY15.232-3.901
TTM11.3315Y10.116+1.215
5Y10.11610Y10.1160.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.3681.919+6.449
MRQ11.0572.051+9.006
TTM11.3312.374+8.957
YOY15.2322.454+12.778
5Y10.1163.737+6.379
10Y10.1164.378+5.738
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Nuvectis Pharma Inc.

4.8.1. Institutions holding Nuvectis Pharma Inc

Institutions are holding 6.976% of the shares of Nuvectis Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Group Inc1.558603011385000019.9094
2024-09-30Baldwin Brothers Inc0.90120.074717413055003.2616
2024-06-30BlackRock Inc0.4317083412-289309-77.6208
2024-09-30Geode Capital Management, LLC0.41260797162648949.7661
2024-09-30Millennium Management LLC0.35450.000268499-50960-42.659
2024-09-30Iridian Asset Management LLC0.28660.074655380553800
2024-09-30GSA Capital Partners LLP0.25950.02385012917903.703
2024-09-30Forbes J M & Co0.25050.0297484019822.0709
2024-09-30Marshall Wace Asset Management Ltd0.22160.000342814894626.4143
2024-09-30Two Sigma Investments LLC0.13860.00042678513741105.3435
2024-09-30Susquehanna International Group, LLP0.137026463264630
2024-09-30Qube Research & Technologies0.11610.00022243314455181.1858
2024-09-30Edmond de Rothschild Holding S.A.0.09920.00191917000
2024-06-30Jane Street Group LLC0.0881017021170210
2024-09-30Renaissance Technologies Corp0.08180.000215800-58700-78.7919
2024-09-30State Street Corp0.079201530000
2024-09-30Northern Trust Corp0.0789015253-34574-69.3881
2024-09-30Baxter Bros Inc0.06470.01021250000
2024-09-30Nations Financial Group Inc0.05180.004610000100000
2024-09-30Citigroup Inc0.04608887400481.9988
Total 5.65820.22081093231-198772-18.2%

4.9.2. Funds holding Nuvectis Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Total Stock Mkt Idx Inv1.19580.000123104000
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr0.29520.00045703000
2024-09-30Fidelity Extended Market Index0.20030.0006387041117240.5782
2024-11-27iShares Micro-Cap ETF0.10980.01122121800
2024-09-30Fidelity Total Market Index0.06910.0001133558987205.7463
2024-09-30BlackRock Extended Equity Market K0.05510.000510640-5-0.047
2024-09-30Fidelity Nasdaq Composite Index0.05290.00041022600
2024-09-30Fidelity Series Total Market Index0.04630.00018938252939.4601
2024-09-30Vanguard Instl Ttl Stck Mkt Idx Tr0.0290.0001561200
2024-10-31Vanguard Balanced Index Inv0.0290.0001560000
2024-10-31Vanguard Instl Ttl Stk Mkt Idx InstlPls0.02610.00015047-565-10.0677
2024-09-30Spartan Extended Market Index Pool E0.02360.00074565160454.1709
2024-09-30NT Ext Equity Mkt Idx Fd - L0.02170.0004419600
2024-09-30Northern Trust Extended Eq Market Idx0.02170.0004419600
2024-09-30Spartan Total Market Index Pool E0.02020.0001389700
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.01880.0003362500
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.01510.0003292190.3091
2024-09-30StoneRidge Dynamic Small Cap0.01460.4202282828280
2024-10-31Schwab Total Stock Market Index0.01210.0001233000
2024-09-301290 VT Micro Cap K0.010.0075193600
Total 2.26640.4437437904+26559+6.1%

5.3. Insider Transactions

Insiders are holding 51.521% of the shares of Nuvectis Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-19Enrique PoradosuBUY20004.99
2024-11-15Ron BentsurBUY200004.92
2024-05-14Ron BentsurBUY19406.74
2024-05-10Enrique PoradosuBUY5006.29
2024-05-10Ron BentsurBUY20006.4
2024-03-18Ron BentsurBUY500010.29
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets17,307
Total Liabilities6,316
Total Stockholder Equity10,991
 As reported
Total Liabilities 6,316
Total Stockholder Equity+ 10,991
Total Assets = 17,307

Assets

Total Assets17,307
Total Current Assets17,307
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 17,169
Other Current Assets 138
Total Current Assets  (as reported)17,307
Total Current Assets  (calculated)17,307
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,316
Long-term Liabilities0
Total Stockholder Equity10,991
Total Current Liabilities
Accounts payable 2,261
Other Current Liabilities 4,055
Total Current Liabilities  (as reported)6,316
Total Current Liabilities  (calculated)6,316
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Retained Earnings -66,997
Other Stockholders Equity 77,988
Total Stockholder Equity (as reported)10,991
Total Stockholder Equity (calculated)10,991
+/-0
Other
Cash and Short Term Investments 17,169
Common Stock Shares Outstanding 17,231
Liabilities and Stockholders Equity 17,307
Net Debt -17,169
Net Working Capital 10,991



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-31
> Total Assets 
0
7,214
6,809
6,657
17,618
14,238
24,866
20,405
16,208
24,941
22,262
19,185
19,714
18,298
17,307
17,30718,29819,71419,18522,26224,94116,20820,40524,86614,23817,6186,6576,8097,2140
   > Total Current Assets 
0
7,214
6,809
5,833
17,618
14,238
24,866
20,405
16,208
24,941
22,262
19,185
19,714
18,298
17,307
17,30718,29819,71419,18522,26224,94116,20820,40524,86614,23817,6185,8336,8097,2140
       Cash And Cash Equivalents 
0
7,214
6,809
5,742
16,693
13,572
23,640
19,993
15,468
24,600
22,059
19,126
19,464
18,116
17,169
17,16918,11619,46419,12622,05924,60015,46819,99323,64013,57216,6935,7426,8097,2140
       Other Current Assets 
0
0
0
91
925
666
1,226
412
740
341
203
59
250
182
138
138182250592033417404121,22666692591000
   > Long-term Assets 
0
0
0
824
0
0
0
0
0
0
0
0
0
0
0
00000000000824000
       Other Assets 
0
0
0
824
0
0
1,226
0
0
0
0
0
0
0
0
000000001,22600824000
> Total Liabilities 
0
11,614
15,741
17,665
3,059
2,738
4,492
6,186
3,934
4,609
5,576
6,984
5,692
5,770
6,316
6,3165,7705,6926,9845,5764,6093,9346,1864,4922,7383,05917,66515,74111,6140
   > Total Current Liabilities 
33
389
495
2,419
3,059
2,738
4,492
6,186
3,934
4,609
5,576
6,984
5,692
5,770
6,316
6,3165,7705,6926,9845,5764,6093,9346,1864,4922,7383,0592,41949538933
       Accounts payable 
33
389
495
1,058
1,349
1,434
2,251
2,910
2,096
1,803
3,492
2,771
1,759
1,846
2,261
2,2611,8461,7592,7713,4921,8032,0962,9102,2511,4341,3491,05849538933
       Other Current Liabilities 
0
0
0
1,361
1,710
1,304
2,241
3,276
1,838
2,806
2,084
4,213
3,933
3,924
4,055
4,0553,9243,9334,2132,0842,8061,8383,2762,2411,3041,7101,361000
   > Long-term Liabilities 
0
11,225
15,246
15,246
1,349
1,434
2,251
2,910
2,096
0
0
0
0
0
0
0000002,0962,9102,2511,4341,34915,24615,24611,2250
       Deferred Long Term Liability 
0
0
0
824
0
0
0
0
0
0
0
0
0
0
0
00000000000824000
> Total Stockholder Equity
0
-4,400
-8,932
-11,008
14,559
11,500
20,374
14,219
12,274
20,332
16,686
12,201
14,022
12,528
10,991
10,99112,52814,02212,20116,68620,33212,27414,21920,37411,50014,559-11,008-8,932-4,4000
   Common Stock
0
0
0
0
0
0
0
0
0
17,231,337
17,326,594
17,768,824
0
18,652,688
0
018,652,688017,768,82417,326,59417,231,337000000000
   Retained Earnings Total Equity00000-41,742-36,034-31,985-25,289-19,412-15,8430000
   Accumulated Other Comprehensive Income 000000000000000
   Capital Surplus 
0
0
0
0
30,402
30,912
45,663
46,204
48,308
62,074
0
0
0
0
0
0000062,07448,30846,20445,66330,91230,4020000
   Treasury Stock000000000000000
   Other Stockholders Equity 
0
1,571
1,707
1,892
12,784
16,674
20,797
46,204
48,308
-17,169,263
-17,262,285
66,446
72,438
75,372
77,988
77,98875,37272,43866,446-17,262,285-17,169,26348,30846,20420,79716,67412,7841,8921,7071,5710



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-22,897
Gross Profit-22,897-22,897
 
Operating Income (+$)
Gross Profit-22,897
Operating Expense-22,897
Operating Income-22,897-45,794
 
Operating Expense (+$)
Research Development15,380
Selling General Administrative7,503
Selling And Marketing Expenses14
Operating Expense22,89722,897
 
Net Interest Income (+$)
Interest Income475
Interest Expense-0
Other Finance Cost-0
Net Interest Income475
 
Pretax Income (+$)
Operating Income-22,897
Net Interest Income475
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-22,260-23,534
EBIT - interestExpense = -21,897
-22,259
-22,260
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-21,897-22,260
Earnings Before Interest and Taxes (EBITDA)-22,897
 
After tax Income (+$)
Income Before Tax-22,260
Tax Provision-0
Net Income From Continuing Ops-22,334-22,260
Net Income-22,260
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses22,897
Total Other Income/Expenses Net637-475
 

Technical Analysis of Nuvectis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nuvectis. The general trend of Nuvectis is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nuvectis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nuvectis Pharma Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 5.85 < 5.85 < 5.9.

The bearish price targets are: 4.6106.

Tweet this
Nuvectis Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nuvectis Pharma Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nuvectis Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartNuvectis Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nuvectis Pharma Inc. The current adx is .

Nuvectis Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Relative Strength Index (RSI) ChartNuvectis Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Stochastic Oscillator ChartNuvectis Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Commodity Channel Index (CCI) ChartNuvectis Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartNuvectis Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Williams %R ChartNuvectis Pharma Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Average True Range (ATR) ChartNuvectis Pharma Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily On-Balance Volume (OBV) ChartNuvectis Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nuvectis Pharma Inc.

Nuvectis Pharma Inc Daily Money Flow Index (MFI) ChartNuvectis Pharma Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nuvectis Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Nuvectis Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nuvectis Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4.710
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Nuvectis with someone you think should read this too:
  • Are you bullish or bearish on Nuvectis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nuvectis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nuvectis Pharma Inc

I send you an email if I find something interesting about Nuvectis Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Nuvectis Pharma Inc.

Receive notifications about Nuvectis Pharma Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.